Table 1.
Epidemiological and clinical characteristics, antifungal treatment and outcome of C. auris candidaemia.
| Characteristics | N = 47 |
|---|---|
| Age, mean (SD) | 61 (16.3) |
| Male | 35 (74.5%) |
| APACHE II, mean (SD) | 15.1 (7.0) |
| Candida score, mean (SD) | 1.48 (1.18) |
| No risk | 9 (19.2%) |
| Low risk | 23 (48.9%) |
| High risk | 15 (31.9%) |
| Charlson comorbidity index, mean (SD) | 3.0 (2.1) |
| Underlying disease | |
| Abdominal surgery | 14 (29.8%) |
| Digestive disease, not surgical | 9 (19.1%) |
| Cardiovascular disease | 7 (14.9%) |
| Neurovascular disease | 5 (10.6%) |
| COVID-19 | 5 (10.6%) |
| Respiratory disease, not COVID-19 | 3 (6.4%) |
| Otorhinolaringologic disease | 2 (4.3%) |
| Politrauma | 2 (4.3%) |
| Risk factors | |
| Diabetes | 13 (27.7%) |
| Malignancy | 12 (25.5%) |
| Immunosuppression | 2 (4.3%) |
| Renal replacement therapy | 8 (17.0%) |
| Total parenteral nutrition | 7 (14.9%) |
| Sepsis | 10 (21.3%) |
| Surgery (<30 days before candidaemia) | 24 (51.1%) |
| Mechanical ventilation | 29 (61.7%) |
| Central venous catheter | 39 (83.0%) |
| Urinary catheter | 38 (80.9%) |
| ICU stay more than two weeks | 33 (70.2%) |
| Previous antibiotic treatment | 43 (91.5%) |
| Days administered: | |
| <7 days | 3 (6.4%) |
| 7 to 14 days | 13 (27.7%) |
| >15 days | 27 (57.4%) |
| Carbapenem use | 25 (53.2%) |
| Previous antifungal treatment (administered for more than 5 days) | 14 (29.8%) |
| Fluconazole | 2 (4.3%) |
| Voriconazole | 1 (2.1%) |
| Echinocandin | 11 (23.4%) |
| Therapeutic measures | |
| Antifungal treatment | 44 (93.6%) |
| Echinocandin in monotherapy | 22 (46.8%) |
| Echinocandin plus Amphotericin B | 12 (25.6%) |
| Echinocandin plus Isavuconazole | 10 (21.3%) |
| Other measures | |
| Central venous catheter removal | 33 (70.2%) |
| Urinary catheter replacement or removal | 3 (6.4%) |
| Outcome | |
| 30-day mortality | 11 (23.4%) |
| Complications | |
| Endophtalmitis | 2 (4.3%) |
| Recurrence of candidaemia | 7 (14.9%) |
| Persistence of candidaemia | 6 (12.8%) |